Alector 2025 Q3 Earnings Beats Estimates as Net Loss Narrows 17.9%

Alector (ALEC) reported fiscal 2025 Q3 earnings on November 6, 2025, with results exceeding Wall Street expectations. , maintaining collaboration revenue targets.

Revenue

, , primarily due to the completion of performance obligations under prior programs.

Earnings/Net Income

, . , , though the company has sustained losses for eight consecutive years. While the EPS improvement is positive, sustained losses over eight years highlight ongoing financial challenges.

Price Action

, reflecting volatile investor sentiment.

Post-Earnings Price Action Review

, . , . The strategy demonstrated resilience and profitability for investors leveraging earnings events.

CEO Commentary

, which targets Alzheimer’s and Parkinson’s therapies. , with preclinical data supporting subcutaneous administration and safety. .

Guidance

, , . , .

Additional News

1. Workforce Reductions, signaling cost-cutting measures to align with financial constraints.

2. Clinical Trial Update, a key milestone for Alzheimer’s disease research.

3. IND Filing Timelines, , respectively, .

, , . .